Glenmede Trust Co. NA Trims Stock Holdings in Quest Diagnostics Incorporated $DGX

Glenmede Trust Co. NA lowered its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 3.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 85,694 shares of the medical research company’s stock after selling 2,882 shares during the quarter. Glenmede Trust Co. NA’s holdings in Quest Diagnostics were worth $16,794,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in DGX. Davis Selected Advisers increased its holdings in Quest Diagnostics by 16.8% in the 4th quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock worth $275,895,000 after buying an additional 228,271 shares during the period. Capital Management Associates Inc purchased a new position in Quest Diagnostics during the 4th quarter worth approximately $1,024,000. ANTIPODES PARTNERS Ltd lifted its stake in Quest Diagnostics by 178.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock valued at $29,847,000 after acquiring an additional 110,280 shares during the period. Advisors Capital Management LLC lifted its stake in Quest Diagnostics by 5.4% during the 4th quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock valued at $54,460,000 after acquiring an additional 16,194 shares during the period. Finally, Artemis Investment Management LLP boosted its holdings in shares of Quest Diagnostics by 6.7% in the 4th quarter. Artemis Investment Management LLP now owns 460,725 shares of the medical research company’s stock valued at $79,950,000 after acquiring an additional 29,084 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insiders Place Their Bets

In related news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 19,747 shares of company stock worth $3,947,088. Company insiders own 0.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DGX shares. Mizuho increased their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. Truist Financial upped their price target on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a report on Friday, July 24th. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. lifted their price objective on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Six research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics presently has a consensus rating of “Hold” and an average target price of $235.31.

Quest Diagnostics Price Performance

Shares of NYSE DGX opened at $233.21 on Friday. The stock has a market capitalization of $25.74 billion, a price-to-earnings ratio of 24.76, a PEG ratio of 2.15 and a beta of 0.58. Quest Diagnostics Incorporated has a 12 month low of $166.76 and a 12 month high of $240.13. The firm’s 50 day simple moving average is $207.36 and its 200-day simple moving average is $199.58. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same period in the previous year, the firm earned $2.62 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were issued a $0.86 dividend. The ex-dividend date of this dividend was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s payout ratio is presently 36.52%.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.